1. Introduction {#sec1}
===============

Cancer is a leading cause of death worldwide and accounted for 8.2 million deaths in the year 2012. Hepatocellular carcinoma (HCC) is the second most common cause of cancer death in the world with 745,000 deaths in the year 2012. In 2013, the World Health Organization (WHO) launched "Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013--2020." The primary objective of this plan is to reduce premature mortality due to cancer, cardiovascular and respiratory disease, and diabetes by 25% \[[@B1]\].

Pakistan stands at the crossroads of socioeconomic insecurity and a keen desire for change \[[@B2]\]. It is the sixth most populous country in the world with estimated population of 182,142,594. As a low income country, we lag behind in various important determinants of healthcare when compared with peer countries. Based on WHO statistics, only 2.7% of total GDP is allocated to health sector (2012), infant mortality is 75.5 per 1000 live births (2012), maternal mortality is 170 per 100,000 live births (2013), and total health expenditure is 77\$ per capita (2012). It is also estimated that 78% of our population pays out of pocket, private sector provides 3/4 of total healthcare, and there are twice as many doctors as nurses for our patients \[[@B3]\].

Cancer incidence and mortality are increasing in the developing world. Pakistan faces sinister limitations in cancer care that have an adverse impact on patient outcomes \[[@B4]\]. A steady increase in the incidence of hepatobiliary cancers has been observed. Based on results of a reliable hospital-based registry in Pakistan, hepatobiliary cancers are the most common malignancy in adult males and represent 10.7% of all cancers \[[@B5]\]. The age standardized rate for HCC in Pakistan is 7.6 per 100,000 persons per year for males and 2.8 for females \[[@B6]--[@B8]\]. Our knowledge on HCC in Pakistani population is limited and primarily reflects single center experiences. Data on HCC is derived from hepatitis B (hep-B) and hepatitis C (hep-C) patients and we are unaware of the natural history of non-hep-B/hep-C HCC in our population \[[@B9]\]. It is estimated that 60--70% HCC in Pakistan is attributable to hep-C. This is different from many other Asian Pacific countries where hep-B remains the predominant etiology \[[@B10]--[@B13]\]. Cancer care in developing countries is compromised but HCC is unique in a number of ways. It has geographical variation, treatment remains controversial, and resource intensive and technical competency alters the outcome considerably. Additionally, various obstacles limit access to standard healthcare and a delayed diagnosis unfortunately yields poor outcomes. Therefore applicability of established guidelines remains questionable in Pakistan and yet we lack a national consensus on HCC management.

Here, we have reviewed the epidemiology of HCC along with diagnostic interventions and treatments offered to Pakistani patients. Factors that lead to late presentation have also been discussed. We have elaborated upon the impact of emerging therapies on HCC in Pakistan and attempted to outline guidelines for better provision of care to our patients.

2. Risk Factors and Epidemiology {#sec2}
================================

Well known risk factors for HCC include alcohol consumption, chronic infection with hepatitis C and hepatitis B, autoimmune hepatitis, hereditary hemochromatosis, alpha-1 antitrypsin deficiency, Wilson disease, and porphyrias \[[@B14], [@B15]\]. There is increasing evidence that diabetes and obesity are linked to HCC \[[@B16]--[@B18]\].

2.1. Pakistan\'s Outlook {#sec2.1}
------------------------

In the absence of a national registry for cancer patients, data primarily comes from single center experiences or scattered regional registries \[[@B6]--[@B8], [@B19], [@B20]\]. Most patients present in the fifth decade of life \[[@B21]--[@B23]\]. Hep-C is the most common etiology in up to 58% patients and hep-B in 25.3% cases \[[@B13]\]. Results from larger studies (*N* ≥ 100) on HCC are conflicting where anti-HCV antibody positivity ranges between 24 and 72.5% while HbsAg positivity varies between 13.1 and 51.2% \[[@B9], [@B24]--[@B29]\]. This can be attributed to patchy nature of available information, high prevalence of hep-C in certain regions of the country, and lack of national cancer surveillance. Analysis of molecular evolution points towards a distinct phylogenetic cluster of HCV-IIIa in our region around 1920s which was followed by a rapid exponential growth in 1950s. As a result, epidemic spread of HCV-IIIa occurred in Pakistan much earlier than other countries \[[@B11]\]. Factors implicated in spread of hep-C virus include a predominantly rural population (66%), illiteracy, unscreened blood products, and misuse of injectables \[[@B30]\]. Use of unsterilized instruments for shaving, minor surgical procedures, and circumcision is common in certain parts of Pakistan. It was shown that up to 48% barbers use unsterile blades for shaving \[[@B31]\]. This is probably why hep-B is the major factor responsible for HCC in developing Asian countries but not the most common etiology in Pakistan \[[@B32]\]. A rise in non-hep-B-hep-C HCC has also been observed. Underlying factors include rising incidence of diabetes, obesity, and aflatoxins \[[@B13], [@B33]--[@B35]\].

To summarize, risk factors for HCC are not different in Pakistan than the rest of the world. Relative frequency of risk factors however is variable and hep-C is by far the most common etiology. As demonstrated in [Figure 1](#fig1){ref-type="fig"}, Pakistan is amongst the few countries in the world with the \>3% prevalence of anti-HCV antibody. We remain unaware of the exact prevalence of non-hep-B-C HCC in Pakistan but increasingly sedentary life style, obesity, diabetes, and poor quality of food have an important role to play.

3. Incidence and Mortality {#sec3}
==========================

Approximately 85% of global liver cancer burden is in Asia and Africa. China, Korea, and Japan are Asian countries with incidence greater than 20/100,000 population. In contrast, Northern Europe and North America are low incidence zones with incidence of HCC \< 10/100,000 population.

3.1. Pakistan\'s Outlook {#sec3.1}
------------------------

HCC is associated with male gender. It was shown that Pakistan is amongst few countries along with Zimbabwe, Columbia, and Costa Rica with no gender predilection but this might be changing now \[[@B32], [@B33]\]. Incidence of HCC in Pakistan is on a rise and correlates well with increasing exposure to risk factors for HCC in our population \[[@B10]\]. Recent results show that hepatobiliary cancers might represent the most common malignancy in adult males in our population \[[@B5]\]. Based on available data, age standardized rate for HCC in Pakistan is 7.6 per 100,000 persons per year for males and 2.8 for females \[[@B6]--[@B8]\]. These estimates are based on hospital-based data and do not reflect the true population-based prevalence of HCC in recent years.

4. Screening {#sec4}
============

HCC has a median subclinical period of 3.2 years. In this period screening has the highest impact with early detection and potential for cure \[[@B36], [@B37]\]. Ultrasound (US) can detect tumors as small as 1.6 ± 0.6 cm \[[@B38]\]. Although US has sensitivity and specificity of \>90% in detecting HCC, its efficiency is compromised in liver cirrhosis. Its yield largely depends on expertise of ultrasonographer \[[@B39]\].

Significant differences in regional guidelines on HCC screening and diagnosis exist. European association on study of liver-European organization for research and treatment of cancer (EASL-EORTC) recommends against the use of serum alpha fetoprotein (AFP) for regular screening given its low specificity and additional cost per primary liver cancer detected (\$1982 (US alone) versus \$3639 (AFP + US)) \[[@B40], [@B41]--[@B43]\]. Asian Oncology Summit (AOS) recommends 3--6 monthly US with serum AFP. AOS guidelines are the least stringent given the high incidence of risk factors (hep-B and hep-C) and HCC in this region. In addition AOS recommends an AFP \> 400 ng/mL to be diagnostic for HCC in high risk patients \[[@B44], [@B45]\].

4.1. Pakistan\'s Outlook {#sec4.1}
------------------------

Majority of patients with risk factors for HCC do not undergo screening. We do not have nationally accepted guidelines for screening high risk patients and physicians at large have a variable practice in terms of choice of investigations and time period between them. The most common trend is 6 monthly US and serum AFP level \[[@B46]\]. Many a time, screening US is performed by inexperienced sonographers. Background cirrhosis makes interpretation of US findings difficult. Less than 10% patients are diagnosed with HCC on screening in Pakistan \[[@B9], [@B13]\] and that perhaps explains the delayed presentation and poor prognosis in majority of HCC patients. The association between elevated AFP and HCC diagnosis is variable. HCC might be present in 7.5% to 100% patients with raised AFP \[[@B13], [@B25], [@B47]--[@B49]\]. This heterogeneity primarily stems from variable cut-offs used to define elevated AFP levels.

In summary, as low as 10% patients in Pakistan with risk factors for HCC undergo regular screening and majority of patients are diagnosed when they are symptomatic. For those who are screened; US and AFP are the most frequently performed investigations but the time duration between these investigations, cut-off for elevated AFP, and sonographers\' technical competency remain grey areas. Recently, Pakistan society for study of liver disease (PSSLD) has recommended 6 monthly US for screening in cirrhotic patients.

5. Diagnosis and Staging {#sec5}
========================

Diagnostic criteria in HCC remain controversial. This is particularly true for lesions \< 1 cm in size. For lesions \> 1 cm in size, typical features on CT or MRI are sufficient for establishing a diagnosis. National comprehensive cancer network (NCCN) and EASL-EORTC recommend 4--6 monthly surveillance with US, CT, or MRI for lesions \< 1 cm in size if they do not exhibit typical arterial enhancement and venous washout on CT or MRI. For lesions \> 1 cm but atypical features on imaging, biopsy is recommended if it is likely to alter management \[[@B40], [@B39]\]. AOS however recommends considering \< 1 cm lesions with typical characteristics as HCC. AOS guidelines seem more applicable to Asian continent where HCC is more common, hepatitis B and hepatitis C are prevalent, and appropriate surveillance is difficult. In addition AFP \> 400 is also diagnostic for HCC. Biopsy is recommended in patients with a doubtful diagnosis \[[@B44], [@B45]\].

According to recently concluded BRIDGE study, the most common stage at presentation for patients with HCC remains BCLC stage C except in Japan and Taiwan \[[@B50]\]. Both these countries have initiated national surveillance programs which are still lacking in North America, Europe, and China \[[@B51]--[@B54]\].

5.1. Pakistan\'s Outlook {#sec5.1}
------------------------

Only 1.7% patients are diagnosed on CT findings alone while various combinations of CT, AFP, and histopathology are used in 62.5% patients \[[@B26]\]. Late presentation and advanced cirrhosis in majority patients are contributory. Since fewer than 10% patients are picked up on screening in Pakistan, patients usually have large tumors (≥8 cm) at the time of diagnosis. Tumors larger than 5 cm are seen in 44.3% patients and at presentation; 52--62% patients have more than 1 tumor nodule. In addition 46--87% patients have Child-Pugh stage B or C. Around 86% patients belong to Okuda class II or III and less than 15% patients are amenable to any form of definitive treatment \[[@B9], [@B26]\].

To summarize, patients with HCC generally have advanced disease at presentation and very few of them are eligible for definitive treatment. Since no local guidelines exist for diagnosis of HCC, majority of patients end up undergoing an array of expensive investigations for establishing a diagnosis.

6. Treatment and Survival {#sec6}
=========================

HCC has a poor prognosis even in developed countries and 5-year survival is only 10%. Survival is even worse in developing countries and mortality is roughly equivalent to incidence rates \[[@B14]\]. According to 2015 statistics of International Agency for Research on Cancer (IARC), the mortality to incidence ratio for HCC is 0.95 and geographical patterns of incidence to mortality are nearly uniform \[[@B56]\]. Early detection of HCC is critical in ensuring optimal treatment. Tumor characteristics (size, multinodularity, and vascular invasion), underlying liver function (Child-Pugh score) and performance status (Eastern Cooperative Oncology Group performance status), play an important role in survival \[[@B57]--[@B59]\].

Since prognosis of HCC depends on multiple factors, various algorithms and guidelines have been adopted but have failed to satisfactorily address issues in HCC management. The most widely used algorithm is Barcelona Clinic Liver Cancer (BCLC) staging system. It incorporates tumor characteristics, liver function, and performance status of an individual patient for allocation to different stages. Patients in stages 0 and A are eligible for potentially curative treatment options like surgical resection, transplantation, and local ablation. For patients in stage B, transarterial chemoembolization (TACE) is utilized. Stage C patients are treated with Sorafenib while stage D (terminal) patients are managed supportively \[[@B60]--[@B62]\]. Global trends in HCC treatment are not uniform and are dictated by data collection instruments, availability of treatment facilities, and technical skills. Treatment may vary for the same stage across different regions. TACE is the most frequently used first treatment in North America, Europe, China, and South Korea; PEI/RFA in Japan; and resection in Taiwan ([Figure 2](#fig2){ref-type="fig"}) \[[@B50]\].

Since 25--70% patients with HCC have advanced stage at presentation \[[@B64]--[@B68]\], chemotherapy provides minimal benefit and survival with Sorafenib does not extend beyond a median of 2-3 months \[[@B69], [@B70]\]. Based on results of clinical trials, median overall survival (OS) is 20 months for stage B HCC, 10 months for Stage C HCC treated with Sorafenib, and 3 months for stage D \[[@B69], [@B71]\]. It must be noted that these guidelines are not applicable to all patients and treatment decisions for individual patients should ideally be personalized. Given the complexity of disease, decisions for individual patients should be taken by multidisciplinary teams \[[@B72]--[@B74]\].

6.1. Pakistan\'s Outlook {#sec6.1}
------------------------

Majority of patients in Pakistan only receive supportive care due to advanced stage at presentation. Yusuf and colleagues reviewed outcomes of 584 patients seen in a cancer hospital in Pakistan. Only 79 (13.5%) received definitive treatment while the rest were managed with supportive care \[[@B26]\]. TACE was the most frequent treatment administered in 60.7% of these 79 patients followed by PEI in 21.5% and resection in 17.7% patients. The cumulative probability of survival was 45%, 20%, and 10% at 1, 3, and 5 years. Another study reported outcomes in 645 HCC patients. Again TACE was the most commonly used treatment in 38.2% patients. All patients had BCLC stage B. Only 2.8% patients in this study had BCLC stage 0 or A HCC \[[@B9]\]. It is important to know that these results come from tertiary care hospitals which are well equipped with medical resources. Majority of patients with HCC never reach specialist facility and we are unaware of their outcomes. Although multidisciplinary teams have recently become more popular in Pakistan, even then the majority of patients are being treated by physicians alone and a multidisciplinary input still remains lacking \[[@B75]\].

7. Research on HCC {#sec7}
==================

Globally, research on HCC lags behind certain other cancers, for example, breast. There is paucity of randomized trials and most studies are retrospective clinical observations. In the last 25 years, there have been 46,959 publications on breast cancer from the United States including 3097 clinical trials \[[@B76]\]. We attempted to assess Pakistan\'s contribution to HCC research in the last 25 years. PubMed was searched for publications related to HCC from USA, UK, China, India, and Pakistan. As shown in [Figure 3](#fig3){ref-type="fig"}, China is the major contributor for HCC research. A total of 6976 publications were retrieved from China versus 2436 from all other countries. Contribution in terms of clinical trials was also higher in China as compared to all other countries, that is, 293 versus 124, respectively.

7.1. Pakistan\'s Outlook {#sec7.1}
------------------------

In the last 15 years, 38 publications including 2 clinical trials were conducted in Pakistan. Both these trials assessed outcomes of advanced HCC with sorafenib/gemcitabine or arterial infusion of ifosfamide \[[@B77], [@B78]\]. At present, Pakistan is participating in 4 multicenter HCC clinical trials \[[@B79]\]. The scarcity of data on HCC reflects upon the advanced stage at presentation when most treatment strategies are futile. Limitations in availability of treatment facilities in Pakistan are a contributing factor \[[@B13]\]. Very few centers in Pakistan offer surgical resection for HCC and liver transplantation was not offered at all until recently \[[@B80], [@B81]\]. Treatment facilities for PEI, RFA, and TACE are inadequate and are available predominantly to affording patients who only represent a minor fraction of patients suffering from HCC in Pakistan.

8. Discussion {#sec8}
=============

8.1. National Screening Program {#sec8.1}
-------------------------------

Majority of HCC in Pakistan is hep-C related. Even today, we remain unaware of the exact prevalence of hep-C in Pakistan. It is assumed that around 10 million people in Pakistan are infected with hep-C \[[@B82], [@B83]\]. It is imperative to have a national hep-C and hep-B screening program. This would allow correct estimates of disease burden in our population and present true picture of viral hepatitis. It has been shown that patients diagnosed with HCC during surveillance have less advanced disease, are more likely to be eligible for curative treatment, and are likely to have increased survival \[[@B84]\]. [Table 1](#tab1){ref-type="table"} represents various obstacles and probable solutions for HCC management in Pakistan.

8.2. Public Education {#sec8.2}
---------------------

Hepatitis C and hepatitis B are both preventable. People in Pakistan generally remain unaware of risk factors and need to be educated regarding modes of spread and necessary precautions \[[@B85], [@B86]\]. Appropriate blood product screening, prohibition of reuse of syringes, sterilization of instruments for circumcision, dental procedures, hair cutting, and shaving may tremendously reduce the incidence of hep-C and hep-B infection \[[@B87]\]. Audiovisual dissemination of risk factors for hepatitis and its impact on health outcomes needs to be communicated to the public. In addition patients infected with hepatitis should understand benefits of strict surveillance and treatments available for HCC. [Figure 4](#fig4){ref-type="fig"} demonstrates the BCLC staging algorithm. Based on results from Pakistan, only 10% patients present in early stage and have the potential to be cured. Unfortunately 90% patients present in advanced stage and are not candidates for curative therapy. Our short term goal should be the development of palliative care facilities and better provision of TACE and Sorafenib to patients with advanced HCC. Indeed palliative care is one of the most ignored specialties in Pakistan. In the long term, we need to develop facilities to detect HCC early and increase patient pool eligible for curative therapy. Physician and public awareness regarding risk factors for HCC, screening in the presence of risk factors, and information on treatments available (what and where) in Pakistan is required.

8.3. Diabetes and Obesity {#sec8.3}
-------------------------

According to International Diabetes Federation, Pakistan is among the leading countries with high prevalence of DM and more than 20% population is suffering from diabetes \[[@B88], [@B89]\]. As high as 50% patients with non-hep-B/C HCC have diabetes in Pakistan \[[@B9]\]. It has been shown that patients with HCC and diabetes treated with Sorafenib and metformin have poor outcomes compared with patients with HCC alone due to tumor aggressiveness in the diabetic group \[[@B90]\]. Sedentary life style has contributed enormously. General public needs to be educated regarding association of obesity/diabetes with multiple cancers and inclusion of healthy life style and balanced diet in daily life.

8.4. Development of Infrastructure {#sec8.4}
----------------------------------

Only a handful of centers in Pakistan provide facilities for TACE, RFA, and PEI. As HCC incidence rises, the demand and supply gap will widen significantly. At least one center in every major city should be planned. This can take pressure off from the more specialized centers and long waiting times for treatment can be avoided.

8.5. Acquire Technical Skills {#sec8.5}
-----------------------------

Surgical resection for early stage HCC is performed only in a few centers in Pakistan. Liver transplantation was not offered until 2012, but it is offered now in Islamabad and Lahore. Overall, surgical care for HCC patients is compromised and there is lack of technical skills as specialized HPB centers are emerging but are yet not established. Technical skills for TACE, RFA, and PEI are also restricted to a few centers and population at large is not being benefited. Public sector needs to come forward and attempt to acquire skills and facilities so that they can be provided to community at large.

8.6. Communication, Collective Decision Making {#sec8.6}
----------------------------------------------

HCC is a difficult disease to manage. There is an array of staging algorithms and wide variations exist in the use of treatment modalities. HCC management should be performed collectively by multidisciplinary teams and personalized approach to patient care should be idealized. For physicians managing HCC patients in suburban/rural regions, an online MDT can be established to aid better decision making.

8.7. New Treatments {#sec8.7}
-------------------

After years of research, we are facing an interesting period where new drugs for hepatitis C will be approved every year. In late 2013, Sofosbuvir was approved by FDA in USA and European Medicine Agency in early 2014. In a phase III randomized trial, Sofosbuvir and Ledipasvir have shown a sustained viral response of \>96% \[[@B91]\]. A 12-week course of Sofosbuvir can cost up to 84000 US dollars \[[@B92]\]. The cost has great implications in terms of its availability in low income countries. In 2006, Egypt developed highly specialized centers for treatment of hepatitis C and brought the cost of Peg-interferon and ribavirin down to \<10% of its cost in USA via successful negotiations with the pharmaceutical companies. Within 6 years of this program, 300,000 Egyptians were treated \[[@B93]\]. Fortunately, similar negotiations have resulted in a reduction in cost of Sofosbuvir for South Asian patients. It is available in 3000 dollars at appointed places in Pakistan. A sustained commitment from Pakistani government can ensure easy availability of these drugs to treat more patients. More transplant centers need to be developed as transplant provides one of the best forms of definitive treatment for patients with HCC. Internationally there is a growing debate over expansion of donor criteria for liver transplant \[[@B94]\]. Better systemic chemotherapy, targeted agents, and immune therapy need to be developed due to limited impact of existing systemic therapies \[[@B95]\]. Various genetic and molecular pathways have been explored. It has been suggested that understanding of epigenetic and genetic processes in HCC might help overcome therapeutic stranding in HCC \[[@B96]\].

8.8. Training Future Caregivers {#sec8.8}
-------------------------------

At present, very few physicians return to Pakistan after receiving advanced training in other countries. Local doctors interested in treatment of patients with liver diseases should be contracted for training and offered viable positions to ensure adequate numbers of healthcare personnel in the country.

8.9. National Cancer Registry {#sec8.9}
-----------------------------

It is high time that a national cancer registry is developed. We need to have correct estimates of healthcare burden in general and cancer in particular in our population. It is difficult to develop a national policy/guideline based on results of scattered registries or hospital data. The true incidence and prevalence of various cancers needs to be registered so that a national action plan can be developed accordingly.

9. Conclusion {#sec9}
=============

HCC in Pakistan is likely to consume significant hospital resources and drain a sizeable chunk of health budget in the future. Although HCC is a multifaceted disease, it largely remains preventable. Surprisingly, general population remains unaware of simple measures that can drastically reduce its occurrence. A balanced approach is required in trying to combat HCC. Prevention, surveillance, and appropriate treatment can significantly improve outcomes and decrease incidence of HCC in Pakistan.
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###### 

Guidelines for HCC management in Pakistan.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Issues                                                                    Potential solutions
  ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  Incidence and prevalence of hepatitis C and hepatitis B are unknown       Implementation of national screening program

                                                                            

  Lack of awareness regarding risk factors\                                 Public education via audiovisual dissemination regarding risk factor prevention, maintenance of healthy life style, and exercise
  Low screening rate\                                                       
  High prevalence of diabetes and obesity                                   

                                                                            

  Insufficient HPB/liver transplant, palliative care, and cancer centers\   Development of infrastructure with collaboration of public and private sector
  Enormous demand and supply gap                                            

                                                                            

  Shortage of technical skills                                              Acquire technical skills via international exposure and collaboration

                                                                            

  Controversial aspects of HCC management\                                  Collective decision making\
  Knowledge gap                                                             Online tumor boards\
                                                                            Personalized care for individual patients

                                                                            

  Low remission rates for hepatitis C                                       Access to new treatments at affordable price

                                                                            

  Physician shortage                                                        Train future caregivers\
                                                                            Incentivization

                                                                            

  Scattered cancer registries\                                              National cancer registry
  True cancer incidence and prevalence unknown                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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